Top ▲

Glucocorticoid receptor

Click here for help

Immunopharmacology Ligand  Target has curated data in GtoImmuPdb

Target id: 625

Nomenclature: Glucocorticoid receptor

Systematic Nomenclature: NR3C1

Family: 3C. 3-Ketosteroid receptors

Contents:

Gene and Protein Information Click here for help
Species AA Chromosomal Location Gene Symbol Gene Name Reference
Human 777 5q31.3 NR3C1 nuclear receptor subfamily 3 group C member 1 42
Mouse 783 18 21.09 cM Nr3c1 nuclear receptor subfamily 3, group C, member 1 26
Rat 795 18p11 Nr3c1 nuclear receptor subfamily 3, group C, member 1 69
Previous and Unofficial Names Click here for help
GCCR | GCR | GR | Type II glucocorticoid receptor | nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) | nuclear receptor subfamily 3
Database Links Click here for help
Alphafold P04150 (Hs), P06537 (Mm), P06536 (Rn)
CATH/Gene3D 3.30.50.10
ChEMBL Target CHEMBL2034 (Hs), CHEMBL3144 (Mm), CHEMBL3368 (Rn)
DrugBank Target P04150 (Hs)
Ensembl Gene ENSG00000113580 (Hs), ENSMUSG00000024431 (Mm), ENSRNOG00000014096 (Rn)
Entrez Gene 2908 (Hs), 14815 (Mm), 24413 (Rn)
Human Protein Atlas ENSG00000113580 (Hs)
KEGG Gene hsa:2908 (Hs), mmu:14815 (Mm), rno:24413 (Rn)
OMIM 138040 (Hs)
Orphanet ORPHA123916 (Hs)
Pharos P04150 (Hs)
RefSeq Nucleotide NM_000176 (Hs), NM_008173 (Mm), NM_012576 (Rn)
RefSeq Protein NP_001019265 (Hs), NP_001191194 (Hs), NP_000167 (Hs), NP_001018661 (Hs), NP_032199 (Mm), NP_036708 (Rn)
SynPHARM 84619 (in complex with budesonide)
6573 (in complex with cortisol)
6570 (in complex with dexamethasone)
84539 (in complex with GSK866)
8010 (in complex with [3H]dexamethasone)
UniProtKB P04150 (Hs), P06537 (Mm), P06536 (Rn)
Wikipedia NR3C1 (Hs)
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  Glucocorticoid receptor- ligand binding domain (bound to an agonist)
PDB Id:  1P93
Ligand:  dexamethasone
Resolution:  2.7Å
Species:  Human
References:  57
Natural/Endogenous Ligands Click here for help
aldosterone
corticosterone
cortisol
deoxycorticosterone
deoxycortisone
Comments: Cortisol and corticosterone are the principal endogenous agonists
Rank order of potency (Human)
cortisol, corticosterone >> aldosterone, deoxycortisone  [95]

Download all structure-activity data for this target as a CSV file go icon to follow link

Agonists Click here for help
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
clobetasol propionate Small molecule or natural product Approved drug Primary target of this compound Ligand has a PDB structure Immunopharmacology Ligand Hs Agonist 9.2 pKi 1
⤷ pKi 9.2 (Ki 6.62x10-10 M) [1]
C108297 Small molecule or natural product Immunopharmacology Ligand Hs Agonist 9.1 pKi 18
⤷ pKi 9.1 (Ki 7x10-10 M) [18]
compound 17 [PMID: 29741897] Small molecule or natural product Immunopharmacology Ligand Hs Agonist 9.1 pKi 32
⤷ pKi 9.1 (Ki 7.6x10-10 M) [32]
Description: Binding Ki.
desoximetasone Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Agonist 8.9 pKi 1
⤷ pKi 8.9 (Ki 1.17x10-9 M) [1]
fluorometholone Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Agonist 8.8 pKi 1
⤷ pKi 8.8 (Ki 1.58x10-9 M) [1]
ORG 214007-0 Small molecule or natural product Immunopharmacology Ligand Hs Partial agonist 8.7 pKi 111
⤷ pKi 8.7 (Ki 2.2x10-9 M) [111]
Description: In a binding assay.
prednisolone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Full agonist 8.6 pKi 19
⤷ pKi 8.6 (Ki 2.4x10-9 M) [19]
flunisolide Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Agonist 8.6 pKi 1
⤷ pKi 8.6 (Ki 2.42x10-9 M) [1]
diflorasone diacetate Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Agonist 8.5 pKi 1
⤷ pKi 8.5 (Ki 2.91x10-9 M) [1]
beclometasone Small molecule or natural product Approved drug Primary target of this compound Ligand has a PDB structure Immunopharmacology Ligand Hs Full agonist 8.4 pKi 1
⤷ pKi 8.4 (Ki 3.74x10-9 M) [1]
methylprednisolone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Agonist 8.3 pKi 1
⤷ pKi 8.3 (Ki 5.03x10-9 M) [1]
ciclesonide Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Agonist 7.4 pKi 4
⤷ pKi 7.4 (Ki 3.7x10-8 M) [4]
prednisone Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Full agonist 6.3 pKi 1
⤷ pKi 6.3 (Ki 5.21x10-7 M) [1]
velsecorat Small molecule or natural product Ligand has a PDB structure Immunopharmacology Ligand Hs Agonist 9.1 pEC50 5,39
⤷ pEC50 9.1 (EC50 9x10-10 M) [5,39]
Description: Measuring displacement of 3H-dexamethasone from the human GR in a competition radioligand binding assay.
AZD2906 Small molecule or natural product Ligand has a PDB structure Hs Agonist 8.9 pEC50 90
⤷ pEC50 8.9 (EC50 1.3x10-9 M) [90]
Description: Measuring hGR-mediated transactivation in ChaGoK1 cells
ORG 214007-0 Small molecule or natural product Immunopharmacology Ligand Hs Partial agonist 8.3 pEC50 111
⤷ pEC50 8.3 (EC50 5.1x10-9 M) [111]
Description: In a co-factor recruitment assay.
fluticasone propionate Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Agonist 8.1 pEC50 39
⤷ pEC50 8.1 (EC50 9x10-9 M) [39]
AZD9567 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Partial agonist 8.0 pEC50 90
⤷ pEC50 8.0 (EC50 1.1x10-8 M) [90]
Description: In a cellular transactivation assay.
LEO 134310 Small molecule or natural product Immunopharmacology Ligand Hs Agonist 7.8 pEC50 30
⤷ pEC50 7.8 (EC50 1.4x10-8 M) [30]
Description: In a GR binding assay
budesonide Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Agonist 7.4 – 7.9 pEC50 39,70
⤷ pEC50 7.9 (EC50 1.24x10-8 M) [70]
pEC50 7.4 (EC50 3.8x10-8 M) [39]
fluticasone propionate Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Agonist 9.3 pIC50 6
⤷ pIC50 9.3 (IC50 5x10-10 M) [6]
Description: Inhibition of [3H]dexamethasone binding to recombinant human glucocorticoid receptor ecpressed in Tni cells.
dagrocorat Small molecule or natural product Immunopharmacology Ligand Hs Partial agonist 8.9 pIC50 94
⤷ pIC50 8.9 (IC50 1.31x10-9 M) [94]
Description: Measured in a glucocorticoid receptor fluorescence polarization ligand binding (GRFP) assay.
dexamethasone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Agonist 8.1 – 9.0 pIC50 38,65,95
⤷ pIC50 8.1 – 9.0 [38,65,95]
ABBV-3373 Peptide Immunopharmacology Ligand Hs Agonist 8.5 pIC50 41
⤷ pIC50 8.5 (IC50 3x10-9 M) [41]
Description: GR binding, for the payload component of this ADC
fluocinolone acetonide Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Agonist 8.5 pIC50 1
⤷ pIC50 8.5 (IC50 3.13x10-9 M) [1]
GSK866 Small molecule or natural product Primary target of this compound Ligand has a PDB structure Immunopharmacology Ligand Hs Agonist 8.5 pIC50 67
⤷ pIC50 8.5 (IC50 3.16x10-9 M) [67]
AZD9567 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Partial agonist 8.4 pIC50 90
⤷ pIC50 8.4 (IC50 3.8x10-9 M) [90]
Description: Binding to human GR in vitro .
fluocinonide Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Agonist 8.3 pIC50 1
⤷ pIC50 8.3 (IC50 5.26x10-9 M) [1]
triamcinolone acetonide Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Agonist 8.2 pIC50 33,120
⤷ pIC50 8.2 [33,120]
CpdA (parent molecule) Small molecule or natural product Immunopharmacology Ligand Mm Agonist 8.2 pIC50 27
⤷ pIC50 8.2 (IC50 6.4x10-9 M) [27]
Description: Whole-cell binding assay performed in L929sA cells, measuring displacement of with [3H]DEX binding to the endogenous mGR.
betamethasone Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Full agonist 8.1 pIC50 1
⤷ pIC50 8.1 (IC50 7.74x10-9 M) [1]
prednisolone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Full agonist 7.8 – 8.1 pIC50 65,90
⤷ pIC50 8.1 (IC50 7x10-9 M) [90]
Description: Binding to human GR in vitro.
pIC50 7.8 (IC50 1.58x10-8 M) [65]
triamcinolone Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Agonist 7.7 pIC50 65
⤷ pIC50 7.7 [65]
ZK216348 Small molecule or natural product Hs Agonist 7.7 pIC50 98
⤷ pIC50 7.7 (IC50 2.03x10-8 M) [98]
cortisol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand is endogenous in the given species Ligand has a PDB structure Immunopharmacology Ligand Hs Agonist 7.3 – 8.0 pIC50 38,65,95
⤷ pIC50 7.3 – 8.0 [38,65,95]
corticosterone Small molecule or natural product Primary target of this compound Ligand is endogenous in the given species Ligand has a PDB structure Immunopharmacology Ligand Mm Agonist 7.2 pIC50 38,65,95
⤷ pIC50 7.2 [38,65,95]
deoxycorticosterone Small molecule or natural product Click here for species-specific activity table Ligand is endogenous in the given species Ligand has a PDB structure Hs Agonist 7.2 pIC50 65,95
⤷ pIC50 7.2 [65,95]
BI 653048 Small molecule or natural product Immunopharmacology Ligand Hs Agonist 7.2 pIC50 35
⤷ pIC50 7.2 (IC50 7x10-8 M) [35]
fosdagrocorat Small molecule or natural product Immunopharmacology Ligand Hs Partial agonist 7.1 pIC50 94
⤷ pIC50 7.1 (IC50 7.9x10-8 M) [94]
Description: Measured in a glucocorticoid receptor fluorescence polarization ligand binding (GRFP) assay.
RU28362 Small molecule or natural product Hs Agonist - -
⤷
RU26988 Small molecule or natural product ? Agonist - -
⤷
[3H]dexamethasone Small molecule or natural product Ligand is labelled Ligand is radioactive Ligand has a PDB structure Hs Agonist - -
⤷
fluticasone Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Agonist - -
⤷
difluprednate Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Agonist - - 104
⤷ [104]
mometasone Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Agonist - -
⤷
mapracorat Small molecule or natural product Primary target of this compound Immunopharmacology Ligand Hs Agonist - - 99
⤷ [99]
benzodrocortisone Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Agonist - - 29
⤷ [29]
View species-specific agonist tables
Agonist Comments
Cortisol is the main glucocorticoid in humans whereas corticosterone is the main form in rodents. Dexamethasone, cortisol and deoxycorticosterone all have high affinity for mineralocorticoid receptors as well.

Note that for ciclesonide, the affinity appears low. However, this is because ciclesonide is a prodrug. The active metabolite, desisobutyrylciclesonide, has a higher affinity of 0.31nM (Ki) [4].

ZK216348 is classified as a SEGRA (Selective Glucocorticoid Receptor Agonist).

C108297 is a selective glucocorticoid receptor (GR) modulator (binding Ki of 0.7 nM) that attenuates obesity by reducing caloric intake and increasing lipolysis and fat oxidation. In addition it reduces inflammation by decreasing macrophage infiltration and pro-inflammatory cytokine expression in white adipose tissue (WAT), as well as in vitro LPS-stimulated TNF-α secretion in macrophage RAW 264.7 cells [110].
Antagonists Click here for help
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
mifepristone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Antagonist 9.4 pKd 37,95
⤷ pKd 9.4 [37,95]
dazucorilant Small molecule or natural product Hs Antagonist 9.6 pKi 47
⤷ pKi 9.6 (Ki 2.8x10-10 M) [47]
Description: Determined in a glucocorticoid receptor competitor fluorescence polarization- displacing fluormone GS Red.
miricorilant Small molecule or natural product Primary target of this compound Hs Antagonist 8.1 pKi 48
⤷ pKi 8.1 (Ki 8x10-9 M) [48]
Description: Determined by measuring displacement of [3H]dexamethasone from recombinant baculovirus derived human GR.
AZD5423 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Antagonist 10.3 pIC50 39
⤷ pIC50 10.3 (IC50 4.9x10-11 M) [39]
Description: Measuring transrepression of glucocorticoid receptor-mediated transcriptional activity in PMA-stimulated human ChaGoK1 cells
ORIC-101 Small molecule or natural product Hs Antagonist 8.3 pIC50 89
⤷ pIC50 8.3 (IC50 5.6x10-9 M) [89]
Description: Inhibitory potency determined in a GR luciferase antagonist assay.
onapristone Small molecule or natural product Click here for species-specific activity table Hs Antagonist 7.6 pIC50 123
⤷ pIC50 7.6 (IC50 2.7x10-8 M) [123]
ZK112993 Small molecule or natural product Click here for species-specific activity table Hs Antagonist - -
⤷
Other Binding Ligands
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Value Parameter Reference
vamorolone Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Binding - - 36,87
⤷ [36,87]
Immunopharmacology Comments
The glucocorticoid receptor (GR) is a long-standing anti-inflammatory drug target, with a large number of synthetic glucocorticoids being used in the clinic for various immune-related disorders and hematological cancers. Glucocorticoids exert anti-inflammatory effects principally by repressing expression of the transcription factors AP-1 and NF-κB, and repression of pro-inflammatory genes. GR signaling facilitates an interface between the endocrine stress response and the immune system that is essential for restoring immune homeostasis following a response to stress (e.g. infection by a pathogen). Glucocorticoid-mediated immune regulation is reviewed by Cain and Cidlowski (2017) [12]. Evidence indicative of pro-inflammatory actions of glucocorticoids is scrutinised in Cruz-Topete and Cidlowski (2015) [24].
DNA Binding Click here for help
Structure:  Homodimer, Heterodimer, RXR partner
HRE core sequence:  GGTACANNNTGTTCT
Response element:  GRE, Half site, Palindrome
Structure:  Monomer
HRE core sequence:  CTCC(n)0-2GGAGA
Response element:  GRE, Palindrome, Other - see comments
DNA Binding Comments
negative GRE [45,103]
Co-binding Partners Click here for help
Name Interaction Effect Reference
C/EBPalpha Physical, Functional DNA binding 96
Retinoid X receptor-α Physical, Functional DNA binding
HMGD Physical, Functional DNA binding 7,112
AP1 Physical, Functional transactivation 51,100,119
NF-κB Physical, Functional transactivation 13,97
14-3-3ρ Physical, Functional cellular localization, transactivation 58
HSP90 Physical, Functional Cellular localization 80-82
HSP70 Physical, Functional Cellular localization 53
Calreticulin Physical, Functional Inhibition of GR binding to GRE
STAT3 Physical, Functional Transactivation 122
T-bet Physical, Functional Transactivation 64
STAT5 Physical, Functional Transactivation 102
p53 Physical, Functional Inhibition of GR binding to GRE 121
Main Co-regulators Click here for help
Name Activity Specific Ligand dependent AF-2 dependent Comments References
MED1 Co-activator No Yes Yes 83
NCOA2 Co-activator No Yes Yes 43,106,113
CREBBP Co-activator No Yes Yes Histone acetyltransferase, a transcriptional cointegrator 52
PTMS Co-activator Yes Yes No Has little effect on ER-mediated transactivation. 78
NCOA6 Co-activator No Yes Yes Likely a member of multimeric complex including NIF-1. 63
BAG1 Co-repressor No No Yes A regulator of HSP70 and a co-repressor. 62
NCOR1 Co-repressor No No - 84,103
SMARCD1 Co-activator No No No Mediates interaction with SWI/SNF complex 44
TADA2A Co-activator No No No Involved in chromatin remodeling 40
SMARCA1 Co-activator No No Yes 15
Main Target Genes Click here for help
Name Species Effect Technique Comments References
NR3C1 Human Repressed ChIP Also observed in rodents 84
FKBP5 Human Activated 109
GZMA Human Activated 109
PCK1 Human Both ChIP, Transient transfection 14
Dusp1 Mouse Activated Transient transfection Dusp1 is also known as MAP kinase phosphatase-1 (MKP-1) 56
annexin A1 Human Activated Transient transfection, other Also known as Lipocrotin-1 71,93
Interleukin 8 Human Repressed 105
TNF Human Repressed 115
RCAN1 Human Activated 109
PER1 Rat Activated ChIP 22
TSC22D3 Human Activated ChIP 25,116
Tissue Distribution Click here for help
Ubiquitous
Species:  Human
Technique:  Northern, Q-PCR, in situ, Western, immunohistology, other
References:  16,42,66,75-76
Tissue Distribution Comments
GR is expressed ubiquitously in mammals.
Functional Assays Click here for help
Hyperglycemic effect
Species:  Human
Tissue:  Serum
Response measured:  Blood glucose level is elevated by intravenous injection of glucocorticoids.
References:  101,118
Thymocyte-killing effects.
Species:  Rat
Tissue:  Thymus
Response measured:  Thymus weight. Thymocytes undergo apoptosis in a GR-dependent manner.
References:  17
Dexmethasone suppression.
Species:  Human
Tissue:  Urine, saliva
Response measured:  Endogenous cortisol level is suppressed significantly by exogenous dexamethasone via GR and the hypothalamus-pituitary-adrenal axis.
References:  50
Physiological Consequences of Altering Gene Expression Click here for help
Glucocorticoid receptor is required for foetal heart maturation.
Species:  Mouse
Tissue:  Heart
Technique:  Gene targeting
References:  92
GR -/- mice:- not viable (die a few hours after birth due to respiratory failure).
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells
References:  20-21
Disruption of hypothalamic-pituitary-adrenocortical system in transgenic mice expressing type II glucocorticoid receptor antisense ribonucleic acid permanently impairs T cell function.
Species:  Mouse
Tissue:  Hypothalamic-pituitary-adrenocortical system
Technique:  Antisense olignucleotide
References:  73
CD4+ T cells are trigger and target of the glucocorticoid response that prevents lethal immunopathology in toxoplasma infection.
Species:  Mouse
Tissue:  T cells
Technique:  Gene targeting
References:  61
Acquired deficit of forebrain glucocorticoid receptor produces depression-like changes in adrenal axis regulation and behavior.
Species:  Mouse
Tissue:  Forebrain
Technique:  Gene targeting
References:  8
Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor.
Species:  Mouse
Tissue:  Whole animal
Technique:  Gene targeting
References:  88
Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety.
Species:  Mouse
Tissue:  Nervous system
Technique:  Gene targeting
References:  107
Point mutation in the mouse glucocorticoid receptor preventing DNA binding impairs spatial memory.
Species:  Mouse
Tissue:  Nervous system
Technique:  Gene targeting
References:  77
T-cell glucocorticoid receptor is required to suppress COX-2-mediated lethal immune activation.
Species:  Mouse
Tissue:  T cells
Technique:  Gene targeting
References:  10
Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth.
Species:  Mouse
Tissue:  Liver
Technique:  Gene targeting
References:  108
Inactivation of the glucocorticoid receptor in hepatocytes leads to fasting hypoglycemia and ameliorates hyperglycemia in streptozotocin-induced diabetes mellitus.
Species:  Mouse
Tissue:  Liver
Technique:  Gene targeting
References:  79
Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability.
Species:  Mouse
Tissue:  Forebrain
Technique:  Gene targeting
References:  117
Essential role of stress hormone signaling in cardiomyocytes for the prevention of heart disease.
Species:  Mouse
Tissue:  Heart
Technique:  Gene targeting
References:  74
Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor.
Species:  Mouse
Tissue:  Bone
Technique:  Gene targeting
References:  85
Chronic stress triggers social aversion via glucocorticoid receptor in dopaminoceptive neurons.
Species:  Mouse
Tissue:  Dopamine-releasing neurons
Technique:  Gene targeting
References:  2
Physiological Consequences of Altering Gene Expression Comments
GR -/- mice also present the following at birth:- lungs at birth are severely atelectatic, and development is impaired from day 15.5 p.c. Newborn livers have a reduced capacity to activate genes for key gluconeogenic enzymes. Feedback regulation via the hypothalamic-pituitary-adrenal axis is severely impaired resulting in elevated levels of plasma adrenocorticotrophic hormone (15-fold) and plasma corticosterone (2.5-fold). Accordingly, adrenal glands are enlarged because of hypertrophy of the cortex, resulting in increased expression of key cortical steroid biosynthetic enzymes, such as side-chain cleavage enzyme, steroid 11 β-hydroxylase, and aldosterone synthase. Adrenal glands lack a central medulla and synthesize no adrenaline. They contain no adrenergic chromaffin cells and only scattered noradrenergic chromaffin cells even when analyzed from the earliest stages of medulla development.
Phenotypes, Alleles and Disease Models Click here for help Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Nr3c1tm2Gsc|Tg(Nes-cre)1Kln Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6J * SJL		 MGI:2176172  MGI:95824  MP:0000013 abnormal adipose tissue distribution PMID: 10471508 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0008504 abnormal adrenal chromaffin cell morphology PMID: 7628695 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd		 MGI:95824  MP:0008504 abnormal adrenal chromaffin cell morphology PMID: 10357937 
Nr3c1tm2.1Gsc Nr3c1tm2.1Gsc/Nr3c1tm2.1Gsc
involves: 129P2/OlaHsd		 MGI:95824  MP:0008504 abnormal adrenal chromaffin cell morphology PMID: 10357937 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0008288 abnormal adrenal cortex morphology PMID: 7628695 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0000639 abnormal adrenal gland morphology PMID: 7628695 
Nr3c1+|Nr3c1Gt(ESKN92)Hgs Nr3c1Gt(ESKN92)Hgs/Nr3c1+
B6.Cg-Nr3c1		 MGI:95824  MP:0000639 abnormal adrenal gland morphology PMID: 18697839 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0003962 abnormal adrenaline level PMID: 7628695 
Nr3c1tm2Gsc|Tg(Drd1a-cre)AGsc Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Drd1a-cre)AGsc/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N		 MGI:3761815  MGI:95824  MP:0009748 abnormal behavioral response to addictive substance PMID: 19234455 
Nr3c1+|Nr3c1tm2.1Gsc Nr3c1tm2.1Gsc/Nr3c1+
B6.129P2-Nr3c1		 MGI:95824  MP:0005167 abnormal blood-brain barrier function PMID: 18523311 
Nr3c1tm2Gsc|Tg(Runx2-icre)1Jtuc Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Runx2-icre)1Jtuc/0
involves: 129P2/OlaHsd * FVB/N		 MGI:4455014  MGI:95824  MP:0010119 abnormal bone mineral density PMID: 20519123 
Nr3c1tm2Gsc|Tg(Runx2-icre)1Jtuc Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Runx2-icre)1Jtuc/0
involves: 129P2/OlaHsd * FVB/N		 MGI:4455014  MGI:95824  MP:0008271 abnormal bone ossification PMID: 20519123 
Nr3c1tm2Gsc|Tg(Runx2-icre)1Jtuc Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Runx2-icre)1Jtuc/0
involves: 129P2/OlaHsd * FVB/N		 MGI:4455014  MGI:95824  MP:0000130 abnormal cancellous bone morphology PMID: 20519123 
Nr3c1tm2Ljm|Tg(Lck-cre)548Jxm Nr3c1tm2Ljm/Nr3c1tm2Ljm,Tg(Lck-cre)548Jxm/?
involves: 129S6/SvEvTac * C57BL/6 * CBA		 MGI:2176198  MGI:95824  MP:0000494 abnormal cecum morphology PMID: 12949501 
Nr3c1+|Nr3c1Gt(ESKN92)Hgs Nr3c1Gt(ESKN92)Hgs/Nr3c1+
B6.Cg-Nr3c1		 MGI:95824  MP:0005345 abnormal circulating corticosterone level PMID: 18697839 
Nr3c1tm2Gsc|Tg(Nes-cre)1Kln Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6J * SJL		 MGI:2176172  MGI:95824  MP:0002065 abnormal fear/anxiety-related behavior PMID: 10471508 
Nr3c1tm2Ljm|Tg(Lck-cre)548Jxm Nr3c1tm2Ljm/Nr3c1tm2Ljm,Tg(Lck-cre)548Jxm/?
involves: 129S6/SvEvTac * C57BL/6 * CBA		 MGI:2176198  MGI:95824  MP:0008750 abnormal interferon level PMID: 12949501 
Nr3c1tm2Ljm|Tg(Lck-cre)548Jxm Nr3c1tm2Ljm/Nr3c1tm2Ljm,Tg(Lck-cre)548Jxm/?
involves: 129S6/SvEvTac * C57BL/6 * CBA		 MGI:2176198  MGI:95824  MP:0008751 abnormal interleukin level PMID: 12949501 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0000609 abnormal liver physiology PMID: 7628695 
Nr3c1tm1Ljm Nr3c1tm1Ljm/Nr3c1tm1Ljm
involves: 129S6/SvEvTac * C57BL/6		 MGI:95824  MP:0001176 abnormal lung development PMID: 12165507 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0001176 abnormal lung development PMID: 7628695 
Nr3c1tm1Ljm Nr3c1tm1Ljm/Nr3c1tm1Ljm
involves: 129S6/SvEvTac * C57BL/6		 MGI:95824  MP:0001175 abnormal lung morphology PMID: 12165507 
Nr3c1tm2Gsc|Tg(Wap-cre)1Gsc Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Wap-cre)1Gsc/0
involves: 129P2/OlaHsd * FVB/N		 MGI:3527253  MGI:95824  MP:0009506 abnormal mammary gland alveolus morphology PMID: 15471946 
Nr3c1tm2Gsc|Tg(Wap-cre)1Gsc Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Wap-cre)1Gsc/0
involves: 129P2/OlaHsd * FVB/N		 MGI:3527253  MGI:95824  MP:0006269 abnormal mammary gland growth during pregnancy PMID: 15471946 
Nr3c1tm2Gsc|Tg(Nes-cre)1Kln Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6 * SJL		 MGI:2176172  MGI:95824  MP:0002272 abnormal nervous system electrophysiology PMID: 19234455 
Nr3c1tm2Gsc|Tg(Drd1a-cre)AGsc Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Drd1a-cre)AGsc/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N		 MGI:3761815  MGI:95824  MP:0002272 abnormal nervous system electrophysiology PMID: 19234455 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0003964 abnormal noradrenaline level PMID: 7628695 
Nr3c1tm2Gsc|Tg(Runx2-icre)1Jtuc Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Runx2-icre)1Jtuc/0
involves: 129P2/OlaHsd * FVB/N		 MGI:4455014  MGI:95824  MP:0008395 abnormal osteoblast differentiation PMID: 20519123 
Nr3c1tm2.1Gsc Nr3c1tm2.1Gsc/Nr3c1tm2.1Gsc
involves: 129P2/OlaHsd * 129X1/SvJ		 MGI:95824  MP:0008395 abnormal osteoblast differentiation PMID: 20519123 
Nr3c1tm3Gsc Nr3c1tm3Gsc/Nr3c1tm3Gsc
involves: 129P2/OlaHsd * FVB/N		 MGI:95824  MP:0005006 abnormal osteoblast physiology PMID: 20519123 
Nr3c1tm2.1Gsc Nr3c1tm2.1Gsc/Nr3c1tm2.1Gsc
involves: 129P2/OlaHsd * 129X1/SvJ		 MGI:95824  MP:0005006 abnormal osteoblast physiology PMID: 20519123 
Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1tm1Dage
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0008872 abnormal physiological response to xenobiotic PMID: 19017639 
Nr3c1+|Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1+
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0008872 abnormal physiological response to xenobiotic PMID: 19017639 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0003115 abnormal respiratory system development PMID: 7628695 
Nr3c1tm1Ljm Nr3c1tm1Ljm/Nr3c1tm1Ljm
involves: 129S6/SvEvTac * C57BL/6		 MGI:95824  MP:0009258 abnormal thymocyte apoptosis PMID: 12165507 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0003118 abnormal tracheal-bronchial branching morphogenesis PMID: 7628695 
Nr3c1tm2Ljm|Tg(Lck-cre)548Jxm Nr3c1tm2Ljm/Nr3c1tm2Ljm,Tg(Lck-cre)548Jxm/?
involves: 129S6/SvEvTac * C57BL/6 * CBA		 MGI:2176198  MGI:95824  MP:0008752 abnormal tumor necrosis factor level PMID: 12949501 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0008294 abnormal zona fasciculata morphology PMID: 7628695 
Nr3c1+|Nr3c1Gt(ESKN92)Hgs Nr3c1Gt(ESKN92)Hgs/Nr3c1+
B6.Cg-Nr3c1		 MGI:95824  MP:0008294 abnormal zona fasciculata morphology PMID: 18697839 
Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1tm1Dage
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0008294 abnormal zona fasciculata morphology PMID: 19017639 
Nr3c1+|Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1+
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0008294 abnormal zona fasciculata morphology PMID: 19017639 
Nr3c1+|Nr3c1Gt(ESKN92)Hgs Nr3c1Gt(ESKN92)Hgs/Nr3c1+
B6.Cg-Nr3c1		 MGI:95824  MP:0008293 abnormal zona glomerulosa morphology PMID: 18697839 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0008295 abnormal zona reticularis morphology PMID: 7628695 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0000643 absent adrenal medulla PMID: 7628695 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0000645 absent adrenergic chromaffin cells PMID: 7628695 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd		 MGI:95824  MP:0001742 absent circulating adrenaline PMID: 10357937 
Nr3c1tm2.1Gsc Nr3c1tm2.1Gsc/Nr3c1tm2.1Gsc
involves: 129P2/OlaHsd		 MGI:95824  MP:0001742 absent circulating adrenaline PMID: 10357937 
Nr3c1tm2Ljm|Tg(Camk2a-cre)T50Stl Nr3c1tm2Ljm/Nr3c1tm2Ljm,Tg(Camk2a-cre)T50Stl/?
involves: 129 * BALB/c * C57BL/6 * CBA		 MGI:3531298  MGI:95824  MP:0001899 absent long term depression PMID: 15623560 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0001177 atelectasis PMID: 7628695 
Nr3c1tm2Ljm|Tg(Camk2a-cre)T50Stl Nr3c1tm2Ljm/Nr3c1tm2Ljm,Tg(Camk2a-cre)T50Stl/?
involves: 129 * BALB/c * C57BL/6 * CBA		 MGI:3531298  MGI:95824  MP:0002573 behavioral despair PMID: 15623560 
Nr3c1tm2Ljm|Tg(Lck-cre)548Jxm Nr3c1tm2Ljm/Nr3c1tm2Ljm,Tg(Lck-cre)548Jxm/?
involves: 129S6/SvEvTac * C57BL/6 * CBA		 MGI:2176198  MGI:95824  MP:0009481 cecum inflammation PMID: 12949501 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0001575 cyanosis PMID: 7628695 
Nr3c1tm2Gsc|Tg(Nes-cre)1Kln Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6J * SJL		 MGI:2176172  MGI:95824  MP:0001364 decreased anxiety-related response PMID: 10471508 
Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1tm1Dage
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0005017 decreased B cell number PMID: 19017639 
Nr3c1+|Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1+
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0005017 decreased B cell number PMID: 19017639 
Nr3c1tm2Gsc|Tg(Nes-cre)1Kln Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6J * SJL		 MGI:2176172  MGI:95824  MP:0001258 decreased body length PMID: 10471508 
Nr3c1tm2Gsc|Tg(Nes-cre)1Kln Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6J * SJL		 MGI:2176172  MGI:95824  MP:0001265 decreased body size PMID: 10471508 
Nr3c1tm2Gsc|Tg(Nes-cre)1Kln Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6J * SJL		 MGI:2176172  MGI:95824  MP:0001262 decreased body weight PMID: 10471508 
Nr3c1tm2Gsc|Tg(Runx2-icre)1Jtuc Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Runx2-icre)1Jtuc/0
involves: 129P2/OlaHsd * FVB/N		 MGI:4455014  MGI:95824  MP:0000063 decreased bone density PMID: 20519123 
Nr3c1tm2Gsc|Tg(Nes-cre)1Kln Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6J * SJL		 MGI:2176172  MGI:95824  MP:0010121 decreased bone mineral density PMID: 10471508 
Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1tm1Dage
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0008075 decreased CD4-positive T cell number PMID: 19017639 
Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1tm1Dage
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0008079 decreased CD8-positive T cell number PMID: 19017639 
Nr3c1tm2Gsc|Tg(Nes-cre)1Kln Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6J * SJL		 MGI:2176172  MGI:95824  MP:0002664 decreased circulating adrenocorticotropin level PMID: 10471508 
Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1tm1Dage
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0002664 decreased circulating adrenocorticotropin level PMID: 19017639 
Nr3c1+|Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1+
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0002664 decreased circulating adrenocorticotropin level PMID: 19017639 
Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1tm1Dage
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0002665 decreased circulating corticosterone level PMID: 19017639 
Nr3c1+|Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1+
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0002665 decreased circulating corticosterone level PMID: 19017639 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd		 MGI:95824  MP:0005664 decreased circulating noradrenaline level PMID: 10357937 
Nr3c1tm2.1Gsc Nr3c1tm2.1Gsc/Nr3c1tm2.1Gsc
involves: 129P2/OlaHsd		 MGI:95824  MP:0005664 decreased circulating noradrenaline level PMID: 10357937 
Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1tm1Dage
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0002780 decreased circulating testosterone level PMID: 19017639 
Nr3c1+|Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1+
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0002780 decreased circulating testosterone level PMID: 19017639 
Nr3c1tm2.1Gsc Nr3c1tm2.1Gsc/Nr3c1tm2.1Gsc
involves: 129P2/OlaHsd		 MGI:95824  MP:0008973 decreased erythroid progenitor cell number PMID: 10580006 
Nr3c1tm3Gsc Nr3c1tm3Gsc/Nr3c1tm3Gsc
involves: 129P2/OlaHsd		 MGI:95824  MP:0008973 decreased erythroid progenitor cell number PMID: 10580006 
Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1tm1Dage
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0003884 decreased macrophage cell number PMID: 19017639 
Nr3c1tm2Gsc|Tg(Lck-cre)I57Jxm Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Lck-cre)I57Jxm/0
B6.Cg-Nr3c1 Tg(Lck-cre)I57Jxm		 MGI:2177579  MGI:95824  MP:0008874 decreased physiological sensitivity to xenobiotic PMID: 18523311 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd		 MGI:95824  MP:0008770 decreased survivor rate PMID: 10357937  12495930 
Nr3c1+|Nr3c1tm2.1Gsc Nr3c1tm2.1Gsc/Nr3c1+
B6.129P2-Nr3c1		 MGI:95824  MP:0006414 decreased T cell apoptosis PMID: 16424199 
Nr3c1tm2Gsc|Tg(Lck-cre)I57Jxm Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Lck-cre)I57Jxm/0
B6.Cg-Nr3c1 Tg(Lck-cre)I57Jxm		 MGI:2177579  MGI:95824  MP:0006414 decreased T cell apoptosis PMID: 18523311 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0000642 enlarged adrenal glands PMID: 7628695 
Nr3c1+|Nr3c1Gt(ESKN92)Hgs Nr3c1Gt(ESKN92)Hgs/Nr3c1+
B6.Cg-Nr3c1		 MGI:95824  MP:0000642 enlarged adrenal glands PMID: 18697839 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0008292 enlarged adrenocortical cell nuclei PMID: 7628695 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0000646 enlarged adrenocortical cells PMID: 7628695 
Nr3c1tm2Gsc|Tg(Nes-cre)1Kln Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6J * SJL		 MGI:2176172  MGI:95824  MP:0001753 hypersecretion of corticotropin-releasing hormone PMID: 10471508 
Nr3c1tm2Ljm|Tg(Camk2a-cre)T50Stl Nr3c1tm2Ljm/Nr3c1tm2Ljm,Tg(Camk2a-cre)T50Stl/?
involves: 129 * BALB/c * C57BL/6 * CBA		 MGI:3531298  MGI:95824  MP:0001402 hypoactivity PMID: 15623560 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0006027 impaired respiratory alveologenesis PMID: 7628695 
Nr3c1tm2Gsc|Tg(Nes-cre)1Kln Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6J * SJL		 MGI:2176172  MGI:95824  MP:0005129 increased adrenocorticotropin level PMID: 10471508 
Nr3c1tm2Gsc|Tg(Runx2-icre)1Jtuc Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Runx2-icre)1Jtuc/0
involves: 129P2/OlaHsd * FVB/N		 MGI:4455014  MGI:95824  MP:0001257 increased body length PMID: 20519123 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0001748 increased circulating adrenocorticotropin level PMID: 7628695 
Nr3c1+|Nr3c1Gt(ESKN92)Hgs Nr3c1Gt(ESKN92)Hgs/Nr3c1+
B6.Cg-Nr3c1		 MGI:95824  MP:0002666 increased circulating aldosterone level PMID: 18697839 
Nr3c1+|Nr3c1Gt(ESKN92)Hgs Nr3c1Gt(ESKN92)Hgs/Nr3c1+
B6.Cg-Nr3c1		 MGI:95824  MP:0006375 increased circulating angiotensinogen level PMID: 18697839 
Nr3c1tm3Gsc Nr3c1tm3Gsc/Nr3c1tm3Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0001745 increased circulating corticosterone level PMID: 9604929 
Nr3c1tm2Ljm|Tg(Camk2a-cre)T50Stl Nr3c1tm2Ljm/Nr3c1tm2Ljm,Tg(Camk2a-cre)T50Stl/?
involves: 129 * BALB/c * C57BL/6 * CBA		 MGI:3531298  MGI:95824  MP:0001745 increased circulating corticosterone level PMID: 15623560 
Nr3c1tm2Gsc|Tg(Camk2a-cre/ERT2)2Gsc Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Camk2a-cre/ERT2)2Gsc/0
involves: 129P2/OlaHsd * FVB/N		 MGI:3759303  MGI:95824  MP:0001745 increased circulating corticosterone level PMID: 17683525 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0001745 increased circulating corticosterone level PMID: 7628695 
Nr3c1+|Nr3c1Gt(ESKN92)Hgs Nr3c1Gt(ESKN92)Hgs/Nr3c1+
B6.Cg-Nr3c1		 MGI:95824  MP:0001745 increased circulating corticosterone level PMID: 18697839 
Nr3c1tm2Gsc|Tg(Nes-cre)1Kln Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6J * SJL		 MGI:2176172  MGI:95824  MP:0003367 increased circulating glucocorticoid level PMID: 10471508 
Nr3c1+|Nr3c1Gt(ESKN92)Hgs Nr3c1Gt(ESKN92)Hgs/Nr3c1+
B6.Cg-Nr3c1		 MGI:95824  MP:0009355 increased liver triglyceride level PMID: 18697839 
Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1tm1Dage
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0004875 increased mean systemic arterial blood pressure PMID: 19017639 
Nr3c1+|Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1+
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0004875 increased mean systemic arterial blood pressure PMID: 19017639 
Nr3c1+|Nr3c1Gt(ESKN92)Hgs Nr3c1Gt(ESKN92)Hgs/Nr3c1+
B6.Cg-Nr3c1		 MGI:95824  MP:0005582 increased renin activity PMID: 18697839 
Nr3c1tm2Ljm|Tg(Lck-cre)548Jxm Nr3c1tm2Ljm/Nr3c1tm2Ljm,Tg(Lck-cre)548Jxm/?
involves: 129S6/SvEvTac * C57BL/6 * CBA		 MGI:2176198  MGI:95824  MP:0009763 increased sensitivity to induced morbidity/mortality PMID: 12949501 
Nr3c1tm2Ljm|Tg(Lck-cre)548Jxm Nr3c1tm2Ljm/Nr3c1tm2Ljm,Tg(Lck-cre)548Jxm/?
involves: 129S6/SvEvTac * C57BL/6 * CBA		 MGI:2176198  MGI:95824  MP:0008735 increased susceptibility to endotoxin shock PMID: 12949501 
Nr3c1+|Nr3c1tm2.1Gsc Nr3c1tm2.1Gsc/Nr3c1+
B6.129P2-Nr3c1		 MGI:95824  MP:0004799 increased susceptibility to experimental autoimmune encephalomyelitis PMID: 18523311 
Nr3c1tm2Gsc|Tg(Lck-cre)I57Jxm Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Lck-cre)I57Jxm/0
B6.Cg-Nr3c1 Tg(Lck-cre)I57Jxm		 MGI:2177579  MGI:95824  MP:0004799 increased susceptibility to experimental autoimmune encephalomyelitis PMID: 18523311 
Nr3c1+|Nr3c1Gt(ESKN92)Hgs Nr3c1Gt(ESKN92)Hgs/Nr3c1+
B6.Cg-Nr3c1		 MGI:95824  MP:0006144 increased systemic arterial systolic blood pressure PMID: 18697839 
Nr3c1tm1Ljm Nr3c1tm1Ljm/Nr3c1tm1Ljm
involves: 129S6/SvEvTac * C57BL/6		 MGI:95824  MP:0002058 neonatal lethality PMID: 12165507  12495930 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0002058 neonatal lethality PMID: 7628695 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd		 MGI:95824  MP:0002058 neonatal lethality PMID: 12495930 
Nr3c1tm2.1Gsc Nr3c1tm2.1Gsc/Nr3c1tm2.1Gsc
involves: 129P2/OlaHsd		 MGI:95824  MP:0002058 neonatal lethality PMID: 10357937 
Nr3c1tm3Ljm Nr3c1tm3Ljm/Nr3c1tm3Ljm
involves: 129S6/SvEvTac * FVB/N		 MGI:95824  MP:0002169 no abnormal phenotype detected PMID: 12133953 
Nr3c1tm2Gsc|Tg(Nes-cre)1Kln Nr3c1tm2Gsc/Nr3c1tm2Gsc,Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6J * SJL		 MGI:2176172  MGI:95824  MP:0000066 osteoporosis PMID: 10471508 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd		 MGI:95824  MP:0002081 perinatal lethality PMID: 10357937 
Nr3c1Gt(ESKN92)Hgs Nr3c1Gt(ESKN92)Hgs/Nr3c1Gt(ESKN92)Hgs
B6.Cg-Nr3c1		 MGI:95824  MP:0002082 postnatal lethality PMID: 18697839 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6		 MGI:95824  MP:0001954 respiratory distress PMID: 7628695 
Nr3c1tm1Ljm Nr3c1tm1Ljm/Nr3c1tm1Ljm
involves: 129S6/SvEvTac * C57BL/6		 MGI:95824  MP:0001953 respiratory failure PMID: 12495930 
Nr3c1tm1Gsc Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd		 MGI:95824  MP:0001953 respiratory failure PMID: 12495930 
Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1tm1Dage
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0002768 small adrenal glands PMID: 19017639 
Nr3c1+|Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1+
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0002768 small adrenal glands PMID: 19017639 
Nr3c1tm1Ljm Nr3c1tm1Ljm/Nr3c1tm1Ljm
involves: 129S6/SvEvTac * C57BL/6		 MGI:95824  MP:0001179 thick alveolar septum PMID: 12165507 
Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1tm1Dage
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0008302 thin adrenal cortex PMID: 19017639 
Nr3c1+|Nr3c1tm1Dage Nr3c1tm1Dage/Nr3c1+
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL		 MGI:95824  MP:0008302 thin adrenal cortex PMID: 19017639 
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Asthma, susceptibility to
Disease Ontology: DOID:2841
OMIM: 600807
Role:  Mutations in the GR gene
References:  3,23
Disease:  Childhood acute lymphoblastic leukemia
Synonyms: acute lymphocytic leukemia
Disease Ontology: DOID:9952
OMIM: 613065
Role:  Mutations in the GR gene
References:  34
Disease:  Glucocorticoid resistance, generalized; GCCR
OMIM: 615962
Orphanet: ORPHA786
Comments:  Glucocorticoid resistance has been attributed to various mutations in the glucocorticoid receptor
References:  49,54,59-60,68,114
Disease:  Glucocorticoid resistance, generalized; GCCR
OMIM: 615962
Orphanet: ORPHA786
Role:  Point mutations in the GR gene
References:  9,11
Click column headers to sort
Type Species Amino acid change Nucleotide change Description Reference
Missense Human C421Y 9,11
Missense Human R477H 9,11
Missense Human I559N 9,11
Missense Human D641V 9,11
Missense Human G679S 9,11
Missense Human V729I 9,11
Missense Human I747M 9,11
Missense Human L753F 9,11
Disease:  Glucocorticoid sensitivity
Role:  N363S polymorphism associated with increased sensitivity to glucocorticoids and a resulting increase in body mass index.
References:  46
Click column headers to sort
Type Species Amino acid change Nucleotide change Description Reference
Missense Human N363S 1220A>G 46
Clinically-Relevant Mutations and Pathophysiology Comments
In general glucocorticoid receptor (GR) polymorphisms have been associated with high blood pressure, insulin sensitivity, body mass index, increased visceral fat, and variations in tissue-specific steroid sensitivity. The N363S polymorphism of the GR results in an asparagine to serine amino acid substitution in a modulatory region of the receptor and phosphorylation of serine residues affects activation of GR target genes [28]. Many other diseases have been associated to certain GR polymorphisms, see GR SNPs.
Biologically Significant Variants Click here for help
Type:  Splice variant
Species:  Human
Description:  glucocorticoid receptor α
Protein accession:  NP_000167
References:  31,42
Type:  Splice variant
Species:  Human
Description:  glucocorticoid receptor β
Protein accession:  NP_001018661
References:  31,42
Type:  Splice variant
Species:  Human
Description:  glucocorticoid receptor γ
Protein accession:  NP_001019265
References:  55,86,91
Type:  Splice variant
Species:  Human
Description:  glucocorticoid receptor P
Protein accession:  NP_001191194
References:  72

References

Show »

1. Auerbach SS, DrugMatrix® and ToxFX® Coordinator National Toxicology Program. National Toxicology Program: Dept of Health and Human Services. Accessed on 02/05/2014. Modified on 02/05/2014. DrugMatrix, https://ntp.niehs.nih.gov/drugmatrix/index.html

2. Barik J, Marti F, Morel C, Fernandez SP, Lanteri C, Godeheu G, Tassin JP, Mombereau C, Faure P, Tronche F. (2013) Chronic stress triggers social aversion via glucocorticoid receptor in dopaminoceptive neurons. Science, 339 (6117): 332-5. [PMID:23329050]

3. Barnes PJ, Greening AP, Crompton GK. (1995) Glucocorticoid resistance in asthma. Am J Respir Crit Care Med, 152 (6 Pt 2): S125-40. [PMID:7489120]

4. Belvisi MG, Bundschuh DS, Stoeck M, Wicks S, Underwood S, Battram CH, Haddad el-B, Webber SE, Foster ML. (2005) Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma. J Pharmacol Exp Ther, 314 (2): 568-74. [PMID:15878996]

5. Berger M, Rehwinkel H, Dahmen J, Eriksson A, Hansson T, Hossain N, Klingstedt PT, Lepisto M, Nilsson S, Memmerling M et al.. (2014) Phenyl and benzodioxinyl substituted indazoles derivatives. Patent number: US8916600. Assignee: Astrazeneca Ab, Bayer Pharma Aktiengesellschaft. Priority date: 20/05/2008. Publication date: 23/12/2014.

6. Biggadike K, Angell RM, Burgess CM, Farrell RM, Hancock AP, Harker AJ, Irving WR, Ioannou C, Procopiou PA, Shaw RE et al.. (2000) Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism. J Med Chem, 43 (1): 19-21. [PMID:10633034]

7. Boonyaratanakornkit V, Melvin V, Prendergast P, Altmann M, Ronfani L, Bianchi ME, Taraseviciene L, Nordeen SK, Allegretto EA, Edwards DP. (1998) High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. Mol Cell Biol, 18 (8): 4471-87. [PMID:9671457]

8. Boyle MP, Brewer JA, Funatsu M, Wozniak DF, Tsien JZ, Izumi Y, Muglia LJ. (2005) Acquired deficit of forebrain glucocorticoid receptor produces depression-like changes in adrenal axis regulation and behavior. Proc Natl Acad Sci USA, 102 (2): 473-8. [PMID:15623560]

9. Bray PJ, Cotton RG. (2003) Variations of the human glucocorticoid receptor gene (NR3C1): pathological and in vitro mutations and polymorphisms. Hum Mutat, 21 (6): 557-68. [PMID:12754700]

10. Brewer JA, Khor B, Vogt SK, Muglia LM, Fujiwara H, Haegele KE, Sleckman BP, Muglia LJ. (2003) T-cell glucocorticoid receptor is required to suppress COX-2-mediated lethal immune activation. Nat Med, 9 (10): 1318-22. [PMID:12949501]

11. Brönnegård M, Stierna P, Marcus C. (1996) Glucocorticoid resistant syndromes--molecular basis and clinical presentations. J Neuroendocrinol, 8 (6): 405-15. [PMID:8809670]

12. Cain DW, Cidlowski JA. (2017) Immune regulation by glucocorticoids. Nat Rev Immunol, 17 (4): 233-247. [PMID:28192415]

13. Caldenhoven E, Liden J, Wissink S, Van de Stolpe A, Raaijmakers J, Koenderman L, Okret S, Gustafsson JA, Van der Saag PT. (1995) Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol Endocrinol, 9 (4): 401-12. [PMID:7659084]

14. Cassuto H, Kochan K, Chakravarty K, Cohen H, Blum B, Olswang Y, Hakimi P, Xu C, Massillon D, Hanson RW, Reshef L. (2005) Glucocorticoids regulate transcription of the gene for phosphoenolpyruvate carboxykinase in the liver via an extended glucocorticoid regulatory unit. J Biol Chem, 280 (40): 33873-84. [PMID:16100117]

15. Chan SW, Hong W. (2001) Retinoblastoma-binding protein 2 (Rbp2) potentiates nuclear hormone receptor-mediated transcription. J Biol Chem, 276 (30): 28402-12. [PMID:11358960]

16. Cidlowski JA, Bellingham DL, Powell-Oliver FE, Lubahn DB, Sar M. (1990) Novel antipeptide antibodies to the human glucocorticoid receptor: recognition of multiple receptor forms in vitro and distinct localization of cytoplasmic and nuclear receptors. Mol Endocrinol, 4 (10): 1427-37. [PMID:1704480]

17. Cidlowski JA, Munck A. (1976) Concanavalin A-induced glucocorticoid resistance in rat thymus cells: decreased cytoplasmic and nuclear receptor binding of dexamethasone. J Steroid Biochem, 7 (11-12): 1141-5. [PMID:1025360]

18. Clark RD, Ray NC, Williams K, Blaney P, Ward S, Crackett PH, Hurley C, Dyke HJ, Clark DE, Lockey P et al.. (2008) 1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity. Bioorg Med Chem Lett, 18 (4): 1312-7. [PMID:18226897]

19. Coghlan MJ, Kym PR, Elmore SW, Wang AX, Luly JR, Wilcox D, Stashko M, Lin CW, Miner J, Tyree C et al.. (2001) Synthesis and characterization of non-steroidal ligands for the glucocorticoid receptor: selective quinoline derivatives with prednisolone-equivalent functional activity. J Med Chem, 44 (18): 2879-85. [PMID:11520196]

20. Cole TJ, Blendy JA, Monaghan AP, Krieglstein K, Schmid W, Aguzzi A, Fantuzzi G, Hummler E, Unsicker K, Schütz G. (1995) Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev, 9 (13): 1608-21. [PMID:7628695]

21. Cole TJ, Myles K, Purton JF, Brereton PS, Solomon NM, Godfrey DI, Funder JW. (2001) GRKO mice express an aberrant dexamethasone-binding glucocorticoid receptor, but are profoundly glucocorticoid resistant. Mol Cell Endocrinol, 173 (1-2): 193-202. [PMID:11223190]

22. Conway-Campbell BL, Sarabdjitsingh RA, McKenna MA, Pooley JR, Kershaw YM, Meijer OC, De Kloet ER, Lightman SL. (2010) Glucocorticoid ultradian rhythmicity directs cyclical gene pulsing of the clock gene period 1 in rat hippocampus. J Neuroendocrinol, 22 (10): 1093-100. [PMID:20649850]

23. Corrigan CJ, Brown PH, Barnes NC, Szefler SJ, Tsai JJ, Frew AJ, Kay AB. (1991) Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis, 144 (5): 1016-25. [PMID:1952426]

24. Cruz-Topete D, Cidlowski JA. (2015) One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids. Neuroimmunomodulation, 22 (1-2): 20-32. [PMID:25227506]

25. D'Adamio F, Zollo O, Moraca R, Ayroldi E, Bruscoli S, Bartoli A, Cannarile L, Migliorati G, Riccardi C. (1997) A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity, 7 (6): 803-12. [PMID:9430225]

26. Danielsen M, Northrop JP, Ringold GM. (1986) The mouse glucocorticoid receptor: mapping of functional domains by cloning, sequencing and expression of wild-type and mutant receptor proteins. EMBO J, 5 (10): 2513-22. [PMID:3780669]

27. De Bosscher K, Vanden Berghe W, Beck IM, Van Molle W, Hennuyer N, Hapgood J, Libert C, Staels B, Louw A, Haegeman G. (2005) A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci U S A, 102 (44): 15827-32. [PMID:16243974]

28. Dobson MG, Redfern CP, Unwin N, Weaver JU. (2001) The N363S polymorphism of the glucocorticoid receptor: potential contribution to central obesity in men and lack of association with other risk factors for coronary heart disease and diabetes mellitus. J Clin Endocrinol Metab, 86 (5): 2270-4. [PMID:11344238]

29. Edelman JL, Nehme A. (2013) PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11ß-17-21-TRIOL-3,20-DIONE DERIVATIVES. Patent number: WO2013071010. Assignee: Allergan, Inc.. Priority date: 11/11/2011. Publication date: 16/05/2013.

30. Eirefelt S, Stahlhut M, Svitacheva N, Carnerup MA, Da Rosa JMC, Ewald DA, Marstrand TT, Krogh-Madsen M, Dünstl G, Dack KN et al.. (2022) Characterization of a novel non-steroidal glucocorticoid receptor agonist optimized for topical treatment. Sci Rep, 12 (1): 1501. [PMID:35087193]

31. Encío IJ, Detera-Wadleigh SD. (1991) The genomic structure of the human glucocorticoid receptor. J Biol Chem, 266 (11): 7182-8. [PMID:1707881]

32. Ghidini E, Marchini G, Capelli AM, Carnini C, Cenacchi V, Fioni A, Facchinetti F, Rancati F. (2018) Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases. J Med Chem, 61 (11): 4757-4773. [PMID:29741897]

33. Giannopoulos G, Keichline D. (1981) Species-related differences in steroid-binding specificity of glucocorticoid receptors in lung. Endocrinology, 108 (4): 1414-9. [PMID:7472274]

34. Haarman EG, Kaspers GJ, Pieters R, Rottier MM, Veerman AJ. (2004) Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticod resistance in childhood leukemia. Leukemia, 18 (3): 530-7. [PMID:14724649]

35. Harcken C, Riether D, Liu P, Razavi H, Patel U, Lee T, Bosanac T, Ward Y, Ralph M, Chen Z et al.. (2014) Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate. ACS Med Chem Lett, 5 (12): 1318-23. [PMID:25516791]

36. Heier CR, Damsker JM, Yu Q, Dillingham BC, Huynh T, Van der Meulen JH, Sali A, Miller BK, Phadke A, Scheffer L et al.. (2013) VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med, 5 (10): 1569-85. [PMID:24014378]

37. Heikinheimo O, Kontula K, Croxatto H, Spitz I, Luukkainen T, Lähteenmäki P. (1987) Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. J Steroid Biochem, 26 (2): 279-84. [PMID:3560943]

38. Hellal-Levy C, Couette B, Fagart J, Souque A, Gomez-Sanchez C, Rafestin-Oblin M. (1999) Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. FEBS Lett, 464 (1-2): 9-13. [PMID:10611474]

39. Hemmerling M, Nilsson S, Edman K, Eirefelt S, Russell W, Hendrickx R, Johnsson E, Kärrman Mårdh C, Berger M, Rehwinkel H et al.. (2017) Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases. J Med Chem, 60 (20): 8591-8605. [PMID:28937774]

40. Henriksson A, Almlöf T, Ford J, McEwan IJ, Gustafsson JA, Wright AP. (1997) Role of the Ada adaptor complex in gene activation by the glucocorticoid receptor. Mol Cell Biol, 17 (6): 3065-73. [PMID:9154805]

41. Hobson AD, McPherson MJ, Hayes ME, Goess C, Li X, Zhou J, Wang Z, Yu Y, Yang J, Sun L et al.. (2022) Discovery of ABBV-3373, an Anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody Drug Conjugate. J Med Chem, 65 (23): 15893-15934. [PMID:36394224]

42. Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, Thompson EB, Rosenfeld MG, Evans RM. (1985) Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature, 318 (6047): 635-41. [PMID:2867473]

43. Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR. (1996) GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci USA, 93 (10): 4948-52. [PMID:8643509]

44. Hsiao PW, Fryer CJ, Trotter KW, Wang W, Archer TK. (2003) BAF60a mediates critical interactions between nuclear receptors and the BRG1 chromatin-remodeling complex for transactivation. Mol Cell Biol, 23 (17): 6210-20. [PMID:12917342]

45. Hudson WH, Youn C, Ortlund EA. (2013) The structural basis of direct glucocorticoid-mediated transrepression. Nat Struct Mol Biol, 20 (1): 53-8. [PMID:23222642]

46. Huizenga NA, Koper JW, De Lange P, Pols HA, Stolk RP, Burger H, Grobbee DE, Brinkmann AO, De Jong FH, Lamberts SW. (1998) A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab, 83 (1): 144-51. [PMID:9435432]

47. Hunt HJ, Belanoff JK, Walters I, Gourdet B, Thomas J, Barton N, Unitt J, Phillips T, Swift D, Eaton E. (2017) Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist. J Med Chem, 60 (8): 3405-3421. [PMID:28368581]

48. Hunt HJ, Ray NC, Hynd G, Sutton J, Sajad M, O'Connor E, Ahmed S, Lockey P, Daly S, Buckley G et al.. (2012) Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat. Bioorg Med Chem Lett, 22 (24): 7376-80. [PMID:23131342]

49. Hurley DM, Accili D, Stratakis CA, Karl M, Vamvakopoulos N, Rorer E, Constantine K, Taylor SI, Chrousos GP. (1991) Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest, 87 (2): 680-6. [PMID:1704018]

50. Jerjes WK, Cleare AJ, Wood PJ, Taylor NF. (2006) Assessment of subtle changes in glucocorticoid negative feedback using prednisolone: comparison of salivary free cortisol and urinary cortisol metabolites as endpoints. Clin Chim Acta, 364 (1-2): 279-86. [PMID:16168400]

51. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, Herrlich P. (1990) Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell, 62 (6): 1189-204. [PMID:2169351]

52. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin SC, Heyman RA, Rose DW, Glass CK, Rosenfeld MG. (1996) A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell, 85 (3): 403-14. [PMID:8616895]

53. Kanelakis KC, Shewach DS, Pratt WB. (2002) Nucleotide binding states of hsp70 and hsp90 during sequential steps in the process of glucocorticoid receptor.hsp90 heterocomplex assembly. J Biol Chem, 277 (37): 33698-703. [PMID:12093808]

54. Karl M, Lamberts SW, Detera-Wadleigh SD, Encio IJ, Stratakis CA, Hurley DM, Accili D, Chrousos GP. (1993) Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene. J Clin Endocrinol Metab, 76 (3): 683-9. [PMID:8445027]

55. Kasai Y. (1990) Two naturally-occurring isoforms and their expression of a glucocorticoid receptor gene from an androgen-dependent mouse tumor. FEBS Lett, 274 (1-2): 99-102. [PMID:2253790]

56. Kassel O, Sancono A, Krätzschmar J, Kreft B, Stassen M, Cato AC. (2001) Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J, 20 (24): 7108-16. [PMID:11742987]

57. Kauppi B, Jakob C, Färnegårdh M, Yang J, Ahola H, Alarcon M, Calles K, Engström O, Harlan J, Muchmore S, Ramqvist AK, Thorell S, Ohman L, Greer J, Gustafsson JA, Carlstedt-Duke J, Carlquist M. (2003) The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem, 278 (25): 22748-54. [PMID:12686538]

58. Kino T, Souvatzoglou E, De Martino MU, Tsopanomihalu M, Wan Y, Chrousos GP. (2003) Protein 14-3-3sigma interacts with and favors cytoplasmic subcellular localization of the glucocorticoid receptor, acting as a negative regulator of the glucocorticoid signaling pathway. J Biol Chem, 278 (28): 25651-6. [PMID:12730237]

59. Kino T, Stauber RH, Resau JH, Pavlakis GN, Chrousos GP. (2001) Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus: importance of the ligand-binding domain for intracellular GR trafficking. J Clin Endocrinol Metab, 86 (11): 5600-8. [PMID:11701741]

60. Koper JW, Stolk RP, de Lange P, Huizenga NA, Molijn GJ, Pols HA, Grobbee DE, Karl M, de Jong FH, Brinkmann AO et al.. (1997) Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum Genet, 99 (5): 663-8. [PMID:9150737]

61. Kugler DG, Mittelstadt PR, Ashwell JD, Sher A, Jankovic D. (2013) CD4+ T cells are trigger and target of the glucocorticoid response that prevents lethal immunopathology in toxoplasma infection. J Exp Med, 210 (10): 1919-27. [PMID:23980098]

62. Kullmann M, Schneikert J, Moll J, Heck S, Zeiner M, Gehring U, Cato AC. (1998) RAP46 is a negative regulator of glucocorticoid receptor action and hormone-induced apoptosis. J Biol Chem, 273 (23): 14620-5. [PMID:9603979]

63. Lee SK, Anzick SL, Choi JE, Bubendorf L, Guan XY, Jung YK, Kallioniemi OP, Kononen J, Trent JM, Azorsa D, Jhun BH, Cheong JH, Lee YC, Meltzer PS, Lee JW. (1999) A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J Biol Chem, 274 (48): 34283-93. [PMID:10567404]

64. Liberman AC, Refojo D, Druker J, Toscano M, Rein T, Holsboer F, Arzt E. (2007) The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction. FASEB J, 21 (4): 1177-88. [PMID:17215482]

65. Lind U, Greenidge P, Gillner M, Koehler KF, Wright A, Carlstedt-Duke J. (2000) Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding. J Biol Chem, 275 (25): 19041-9. [PMID:10747884]

66. Lu NZ, Cidlowski JA. (2005) Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcrip